Sep 12, 2022 7:00am EDT Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
Sep 08, 2022 7:00am EDT Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
Sep 01, 2022 7:00am EDT Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Aug 23, 2022 7:15am EDT Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Aug 03, 2022 7:07am EDT Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Jul 28, 2022 7:00am EDT Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Jul 18, 2022 8:00am EDT Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Jul 11, 2022 7:00am EDT Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
